Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
McGill University
$120,000.00
Elucidating the function of EZH2 in modulating cellular plasticity through control of estrogen receptor expression and driving tumor recurrence in breast cancer
FY 2025-26
Summary
Breast cancer accounts for 25% of new cancer cases and is a leading cause of cancer related deaths in women, where resistance to therapy and breast cancer recurrence remain challenges. One protein implicated to be pro-tumorigenic in breast cancer is Enhancer of Zeste Homolog 2 (EZH2). This protein acts within a complex, known as PRC2, which functions to repress gene expression, but it also has PRC-independent functions, which remain poorly understood. In breast cancer patients, EZH2 is often found at higher levels, and this is correlated with poor prognosis, resistance to therapeutics and tumor recurrence. However, the reasons behind many of these observations remain unknown, highlighting the need for further mechanistic validation in pre-clinical models. Our lab has developed genetically engineered mouse models (GEMMs) which mimic human breast cancer, allowing us to effectively study tumour progression and recurrence. Recent work in our lab using an aggressive GEMM has found that removing EZH2 from this model will reduce tumour growth and prevent the cancer spreading to other organs. We specifically discovered that EZH2 loss drives a more luminal-like tumor via upregulation of the estrogen receptor (ER), which can in turn resensitize these aggressive tumors to ER-targeted therapies, although this requires further validation. Further, we have showed that EZH2 loss causes a delayed and lower penetrance of tumor recurrence, although this mechanism appears to be PRC2-independent. Using a combination of GEMMs, patient-derived samples and cellular culture techniques, we will study how EZH2 drives recurrence and utilize well established EZH2 inhibitors and degraders in pre-clinical models to assess their effect on tumor growth and recurrence. Ultimately, we aim to provide rationale for targeting EZH2 in combination with other targeted therapies in both the primary and recurrent setting, ultimately leading to improved patient outcome for patients with breast cancer.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
560257
Name
Massey Eleanor J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Elucidating the function of EZH2 in modulating cellular plasticity through control of estrogen receptor expression and driving tumor recurrence in breast cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Breast Cancer; Breast Cancer Progression; Cancer Relapse/Recurrence; Epigenetics; Estrogen Receptor; Ezh2; Ezh2 Inhibitors/Degraders; Genetically Engineered Mouse Models (Gemms); Prc2 Complex; Therapeutics
Abstract
Breast cancer accounts for 25% of new cancer cases and is a leading cause of cancer related deaths in women, where resistance to therapy and breast cancer recurrence remain challenges. One protein implicated to be pro-tumorigenic in breast cancer is Enhancer of Zeste Homolog 2 (EZH2). This protein acts within a complex, known as PRC2, which functions to repress gene expression, but it also has PRC-independent functions, which remain poorly understood. In breast cancer patients, EZH2 is often found at higher levels, and this is correlated with poor prognosis, resistance to therapeutics and tumor recurrence. However, the reasons behind many of these observations remain unknown, highlighting the need for further mechanistic validation in pre-clinical models. Our lab has developed genetically engineered mouse models (GEMMs) which mimic human breast cancer, allowing us to effectively study tumour progression and recurrence. Recent work in our lab using an aggressive GEMM has found that removing EZH2 from this model will reduce tumour growth and prevent the cancer spreading to other organs. We specifically discovered that EZH2 loss drives a more luminal-like tumor via upregulation of the estrogen receptor (ER), which can in turn resensitize these aggressive tumors to ER-targeted therapies, although this requires further validation. Further, we have showed that EZH2 loss causes a delayed and lower penetrance of tumor recurrence, although this mechanism appears to be PRC2-independent. Using a combination of GEMMs, patient-derived samples and cellular culture techniques, we will study how EZH2 drives recurrence and utilize well established EZH2 inhibitors and degraders in pre-clinical models to assess their effect on tumor growth and recurrence. Ultimately, we aim to provide rationale for targeting EZH2 in combination with other targeted therapies in both the primary and recurrent setting, ultimately leading to improved patient outcome for patients with breast cancer.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Massey, Eleanor J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~